Company Filing History:
Years Active: 2003-2007
Title: Richard Colonno: Innovative Contributions to Hepatitis Treatment
Introduction: Richard Colonno, an accomplished inventor based in Farmington, CT, has made significant strides in the field of pharmaceutical innovation. With a focus on developing effective treatments for viral infections, Colonno holds two patents that demonstrate his commitment to addressing critical health issues. His work primarily revolves around hepatitis C and hepatitis B treatment strategies.
Latest Patents: Colonno's recent patents include groundbreaking research on compounds that inhibit hepatitis C virus (HCV) replication. One of his notable inventions, titled "Iminothiazolidinones as inhibitors of HCV replication," details compounds designed to target the function of the HCV NS5A protein. This research offers promising prospects for combating HCV infection. Additionally, he has developed a patent for "Low dose entecavir formulation and use," which focuses on daily administration of a low dose of entecavir to treat hepatitis B virus infection and co-infections. The formulations allow for the inclusion of other pharmaceutically active substances, enhancing treatment options for affected patients.
Career Highlights: Richard Colonno has made significant contributions while working at Bristol-Myers Squibb Company, a leading pharmaceutical firm known for its commitment to innovation in drug development. His work in the laboratory has been vital in pushing forward new treatment modalities that address viral challenges in healthcare.
Collaborations: Throughout his career, Colonno has collaborated with esteemed colleagues such as Jeffrey Lee Romine and Scott W. Martin. These partnerships have facilitated the exchange of ideas and expertise, propelling advancements in their collective research ventures.
Conclusion: Richard Colonno exemplifies the spirit of innovation and dedication in the pharmaceutical industry. His patents not only highlight his inventive prowess but also reflect a deep commitment to improving the quality of life for individuals affected by viral infections. As his work continues to evolve, the impact of his contributions is sure to resonate within the healthcare community for years to come.